🔗 Share this article

Given that the United States continues making unprecedented adjustments to its vaccine guidelines, one figure has emerged in a surprising turn: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by questioning Covid vaccines in the global health crisis and has concentrated on alleged deaths following COVID-19 immunization in her recent time at the Food and Drug Administration.

Planned Changes to Pediatric Vaccine Program

Health officials had intended to unveil major changes to the pediatric vaccination calendar earlier this month, bringing the US with the Danish vaccine program, it is understood – a substantial departure that would put the US out of alignment with a large portion of the world with no evidence for public health gain. The planned update has been pushed back until the new year.

Rather than Vinay Prasad, Dr. Høeg is set to address the audience at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the division this calendar year.

A New Direction at the Agency

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a increased emphasis upon rolling back long-standing immunizations at the FDA.

The new acting director has repeatedly called for ending some childhood shot schedules in the US so as to align more similar to the Danish model, a country with nationalized medicine and a number of inhabitants about the population of Wisconsin’s.

So far statements, she has persisted in emphasizing on vaccination policy – usually the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Qualifications

Dr. Høeg has little discernible background in drug development, oversight or leadership, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for leading the CDER, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in managing a large organization. She lacks background in industry regulation.”

Past heads of the center would “understand regulatory frameworks and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she doesn’t have the sort of resume that previous people who ran the center have had.”

The drug center has an enormous portfolio at the FDA, she pointed out.

“The public just zeroes in on the novel medication approvals, but the generic program authorizes a multitude of generic drugs. There’s a biologic copycat branch, OTC medication office and other areas, and all of those need to be looked after,” Dr. Woodcock said. “The thing you neglect, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial leadership component to the job, which manages over 5,000 staff members. “It’s a massive management job, if you perform it correctly,” the former official added.

Response and Contentious Initiatives

Regarding concerns about Høeg’s credentials and whether this selection signifies increased cooperation among agency officials on vaccines, a spokesperson responded that the “questions rely on incorrect presumptions”.

“Her resume is consistent with the duties of her position,” the representative explained, pointing to the time Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg takes over the commissioner’s recently launched fast-track approval initiative, a controversial rapid therapy clearance system that reportedly worried her preceding directors. “How are these medications being picked for this fast-track system? Who takes the choices?” Dr. Howard said. “There is a lot of secrecy happening at the agency right now.”

In general, he said, “the agency appears to be shifting towards less stringent rules of most medications, with the exception of shots.”

Established History on Vaccines

Concerning immunizations, Høeg has a clearer, if troubling, history, critics said. She released a study using non-validated crowd-sourced reports to estimate the frequency of myocarditis after COVID-19 immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccinations are riskier than they are.

Included in her “desired changes” for the current administration included revising guidelines for novel immunizations and discontinuing “optional” vaccines, she stated after the election on a podcast. At the agency, Dr. Høeg has reportedly proposed preventing adolescent males from receiving COVID-19 vaccines.

“She is an complete true believer who begins with her beliefs and tailors the evidence to retrofit the data in a extremely disingenuous, fraudulent manner,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with fellow dissenters, {like|